MGC Pharmaceuticals is starting its clinical tests in Slovenia on human volunteers to determine the efficacy of its dermatologcial skin care products •
Company’s dermatological skin care products are targeted for the relief of redness, dryness, flaky and oily indications for skin prone to acne, seborrhea and psoriasis •
MGC Pharmaceuticals expects to commence sales of a dermatological skin care product range by Q3 2017, following the completion of successful clinical tests •
Company aims to market the product range via select retail outlets and pharmacy chains, and the MGC Derma online shop •
Dermatological products represent the Company’s second material revenue stream in 2017, complementing its MGC Derma cosmetics line
MXC Price at posting:
4.1¢ Sentiment: Buy Disclosure: Held
